Valuation: Artiva Biotherapeutics, Inc.

Market Cap 198M 180M 166M 150M 283M 18.69B 292M 2B 791M 9.98B 744M 728M 31.69B P/E 2026 *
-1.46x
P/E 2027 * -2.2x
Enterprise Value 198M 180M 166M 150M 283M 18.69B 292M 2B 791M 9.98B 744M 728M 31.69B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
85.24%
Yield 2026 *
-
Yield 2027 * -
1 day+1.26%
1 week-3.37%
Current month-4.30%
1 month-36.25%
3 months-64.51%
6 months-61.81%
Current year-6.53%
1 week 3.9
Extreme 3.905
4.26
1 month 3.9
Extreme 3.905
6.74
Current year 3.62
Extreme 3.62
14.53
1 year 2.96
Extreme 2.96
14.53
3 years 1.47
Extreme 1.47
17.31
5 years 1.47
Extreme 1.47
17.31
10 years 1.47
Extreme 1.47
17.31
Manager TitleAgeSince
Chief Executive Officer 51 05/01/2021
President 63 18/05/2026
Chief Tech/Sci/R&D Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 40 01/06/2020
Director/Board Member 51 05/01/2021
Chairman 67 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
02/11/26 Sell

Chief Technology Officer

-10,423 0.0213%
02/11/26 Sell

Chief Executive Officer

-62,178 0.1272%
02/11/26 Sell

Compliance Officer

-8,439 0.0173%
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%-3.37% - - 198M
Average +1.26%
Weighted average by Cap. +1.26%

Financials

2026 *2027 *
Net sales - -
Net income -113M -102M -94.76M -85.5M -161M -10.66B -167M -1.14B -451M -5.69B -424M -415M -18.07B -89.01M -80.67M -74.61M -67.32M -127M -8.39B -131M -896M -355M -4.48B -334M -327M -14.23B
Net Debt - -
Projected Income Statement - Annual - Artiva Biotherapeutics, Inc.
Logo Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Employees
134
Date Price Change Volume
13/11/26 $4.010 +1.26% 868,511
12/11/26 $3.960 -2.70% 1,436,866
11/11/26 $4.070 +0.25% 870,854
10/11/26 $4.060 -3.79% 925,853
09/11/26 $4.220 +1.69% 939,953
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Artiva Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.010USD
Average target price
20.75USD
Spread / Average Target
+417.46%
  1. Stock Market
  2. Stocks
  3. ARTV Stock